Jay Duker Buys 1,500 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) CEO Jay Duker acquired 1,500 shares of Eyepoint Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were bought at an average cost of $13.15 per share, with a total value of $19,725.00. Following the completion of the transaction, the chief executive officer owned 100,665 shares of the company’s stock, valued at approximately $1,323,744.75. This trade represents a 1.51% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $13.90 on Wednesday. The company’s 50-day moving average is $15.18 and its 200-day moving average is $14.52. The firm has a market capitalization of $1.16 billion, a PE ratio of -4.40 and a beta of 1.72. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%.The company had revenue of $0.62 million for the quarter, compared to the consensus estimate of $1.01 million. Analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright lifted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Chardan Capital boosted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.20.

Institutional Trading of Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new position in shares of Eyepoint Pharmaceuticals during the 4th quarter worth approximately $53,658,000. Paradigm Biocapital Advisors LP bought a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth approximately $28,556,000. Orbimed Advisors LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the third quarter valued at approximately $25,575,000. Suvretta Capital Management LLC raised its position in shares of Eyepoint Pharmaceuticals by 26.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after buying an additional 1,634,970 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after buying an additional 1,601,101 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.